Markus Joerger
Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.
Addeo A, Rothschild S, Holer L, Schneider M, Waibel C, Haefliger S, Mark M, Fernandez E, Mach N, Mauti L, Jermann P, Alborelli I, Calgua B, Savic-Prince S, Joerger M, Früh M. Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study. Lung Cancer 2022; 172:154-159.
28.08.2022Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.
28.08.2022Lung Cancer 2022; 172:154-159
Addeo Alfredo, Rothschild Sacha I, Holer Lisa, Schneider Martina, Waibel Christine, Haefliger Simon, Mark Michael, Fernandez Eugenio, Mach Nicolas, Mauti Laetitia, Jermann Philip, Alborelli Ilaria, Calgua Byron, Savic-Prince Spasenija, Joerger Markus, Früh Martin
Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis.
Jacobs B, Deenen M, Joerger M, Rosing H, de Vries N, Meulendijks D, Cats A, Beijnen J, Schellens J, Huitema A. Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis. CPT Pharmacometrics Syst Pharmacol 2019; 8:940-950.
20.11.2019Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis.
20.11.2019CPT Pharmacometrics Syst Pharmacol 2019; 8:940-950
Jacobs Bart A W, Deenen Maarten J, Joerger Markus, Rosing Hilde, de Vries Niels, Meulendijks Didier, Cats Annemieke, Beijnen Jos H, Schellens Jan H M, Huitema Alwin D R
Excel-Based Tool for Pharmacokinetically Guided Dose Adjustment of Paclitaxel.
Kraff S, Lindauer A, Joerger M, Salamone S, Jaehde U. Excel-Based Tool for Pharmacokinetically Guided Dose Adjustment of Paclitaxel. Ther Drug Monit 2015; 37:725-32.
01.12.2015Excel-Based Tool for Pharmacokinetically Guided Dose Adjustment of Paclitaxel.
01.12.2015Ther Drug Monit 2015; 37:725-32
Kraff Stefanie, Lindauer Andreas, Joerger Markus, Salamone Salvatore J, Jaehde Ulrich
Treatment regimens of classical and newer taxanes.
Joerger M. Treatment regimens of classical and newer taxanes. Cancer Chemother Pharmacol 2015; 77:221-33.
20.11.2015Treatment regimens of classical and newer taxanes.
20.11.2015Cancer Chemother Pharmacol 2015; 77:221-33
Joerger Markus
Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity.
Kummer D, Froehlich T, Joerger M, Aebi S, Sistonen J, Amstutz U, Largiadèr C. Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity. Pharmacogenomics 2015; 16:1367-77.
05.08.2015Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity.
05.08.2015Pharmacogenomics 2015; 16:1367-77
Kummer Dominic, Froehlich Tanja K, Joerger Markus, Aebi Stefan, Sistonen Johanna, Amstutz Ursula, Largiadèr Carlo R
Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy.
Amstutz U, Offer S, Sistonen J, Joerger M, Diasio R, Largiadèr C. Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy. Clin Cancer Res 2015; 21:2038-44.
05.02.2015Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy.
05.02.2015Clin Cancer Res 2015; 21:2038-44
Amstutz Ursula, Offer Steven M, Sistonen Johanna, Joerger Markus, Diasio Robert B, Largiadèr Carlo R